PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8

Rotavirus infection is among leading causes of severe diarrhea which often leads to severe dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is constantly increased, due to higher rates of actual rotavirus infection cases and improved diagnostics...

Full description

Saved in:
Bibliographic Details
Main Authors: I. V. Dukhovlinov, E. G. Bogomolova, E. A. Fedorova, A. S. Simbirtsev
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2016-08-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/1065
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241478644105216
author I. V. Dukhovlinov
E. G. Bogomolova
E. A. Fedorova
A. S. Simbirtsev
author_facet I. V. Dukhovlinov
E. G. Bogomolova
E. A. Fedorova
A. S. Simbirtsev
author_sort I. V. Dukhovlinov
collection DOAJ
description Rotavirus infection is among leading causes of severe diarrhea which often leads to severe dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is constantly increased, due to higher rates of actual rotavirus infection cases and improved diagnostics of the disease. Immunity to rotavirus is unstable, thus causing repeated infections intra vitam. Anti-infectious resistance in reconvalescents is explained by induction of specific IgM, IgG, and, notably, IgA antibodies. Due to absence of market drugs with direct action against rotavirus, a rational vaccination is considered the most effective way to control the disease. Currently available vaccines for prevention of rotavirus infection are based on live attenuated rotavirus strains, human and/or animal origin, which replicate in human gut. Their implementation may result into different complications. Meanwhile, usage of vaccines based on recombinant proteins is aimed to avoid risks associated with introduction of a complete virus into humans. In this paper, we studied protective activity of candidate vaccines against rotavirus.In this work we studied protective activity of a candidate vaccine against rotavirus infection based on recombinant FliCVP6VP8 protein which includes VP6 and VP8, as well as components of Salmonella typhimurium flagellin (FliC) as an adjuvant. Different components are joined by flexible bridges. Efficiency of the candidate vaccine was studied in animal model using Balb/c mice. We have shown high level of protection which occurs when the candidate vaccine is administered twice intramuscularly. Complete protection of animals against mouse rotavirus EDC after intramuscular immunization with a candidate vaccine was associated with arising rotavirus-specific IgA and IgG antibodies in serum and intestine of immunized animals. The efficacy of candidate vaccine based on recombinant protein FliCVP6VP8 against rotavirus infection was comparable to that of commercial Rotarix® vaccine (Glaxo Smith Kline), however, with higher safety of the candidate vaccine, due to absence of live virus in its composition. Hence, the results obtained justify further pre-clinical studies of the candidate vaccine based on a recombinant protein.
format Article
id doaj-art-57dff952b36b4449afebaa59e528f8cd
institution Kabale University
issn 1563-0625
2313-741X
language Russian
publishDate 2016-08-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj-art-57dff952b36b4449afebaa59e528f8cd2025-08-20T04:00:09ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2016-08-0118541742410.15789/1563-0625-2016-5-417-424856PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8I. V. Dukhovlinov0E. G. Bogomolova1E. A. Fedorova2A. S. Simbirtsev3State Research Institute of Highly Pure Biopreparations, Federal Agency for Medicine and BiologyState Research Institute of Highly Pure Biopreparations, Federal Agency for Medicine and BiologyState Research Institute of Highly Pure Biopreparations, Federal Agency for Medicine and BiologyState Research Institute of Highly Pure Biopreparations, Federal Agency for Medicine and BiologyRotavirus infection is among leading causes of severe diarrhea which often leads to severe dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is constantly increased, due to higher rates of actual rotavirus infection cases and improved diagnostics of the disease. Immunity to rotavirus is unstable, thus causing repeated infections intra vitam. Anti-infectious resistance in reconvalescents is explained by induction of specific IgM, IgG, and, notably, IgA antibodies. Due to absence of market drugs with direct action against rotavirus, a rational vaccination is considered the most effective way to control the disease. Currently available vaccines for prevention of rotavirus infection are based on live attenuated rotavirus strains, human and/or animal origin, which replicate in human gut. Their implementation may result into different complications. Meanwhile, usage of vaccines based on recombinant proteins is aimed to avoid risks associated with introduction of a complete virus into humans. In this paper, we studied protective activity of candidate vaccines against rotavirus.In this work we studied protective activity of a candidate vaccine against rotavirus infection based on recombinant FliCVP6VP8 protein which includes VP6 and VP8, as well as components of Salmonella typhimurium flagellin (FliC) as an adjuvant. Different components are joined by flexible bridges. Efficiency of the candidate vaccine was studied in animal model using Balb/c mice. We have shown high level of protection which occurs when the candidate vaccine is administered twice intramuscularly. Complete protection of animals against mouse rotavirus EDC after intramuscular immunization with a candidate vaccine was associated with arising rotavirus-specific IgA and IgG antibodies in serum and intestine of immunized animals. The efficacy of candidate vaccine based on recombinant protein FliCVP6VP8 against rotavirus infection was comparable to that of commercial Rotarix® vaccine (Glaxo Smith Kline), however, with higher safety of the candidate vaccine, due to absence of live virus in its composition. Hence, the results obtained justify further pre-clinical studies of the candidate vaccine based on a recombinant protein.https://www.mimmun.ru/mimmun/article/view/1065rotavirus gastroenteritisvaccinerecombinant fusion proteinsmouse modelprotective activity
spellingShingle I. V. Dukhovlinov
E. G. Bogomolova
E. A. Fedorova
A. S. Simbirtsev
PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
Медицинская иммунология
rotavirus gastroenteritis
vaccine
recombinant fusion proteins
mouse model
protective activity
title PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
title_full PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
title_fullStr PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
title_full_unstemmed PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
title_short PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8
title_sort protective activity study of a candidate vaccine against rotavirus infection based on recombinant protein flicvp6vp8
topic rotavirus gastroenteritis
vaccine
recombinant fusion proteins
mouse model
protective activity
url https://www.mimmun.ru/mimmun/article/view/1065
work_keys_str_mv AT ivdukhovlinov protectiveactivitystudyofacandidatevaccineagainstrotavirusinfectionbasedonrecombinantproteinflicvp6vp8
AT egbogomolova protectiveactivitystudyofacandidatevaccineagainstrotavirusinfectionbasedonrecombinantproteinflicvp6vp8
AT eafedorova protectiveactivitystudyofacandidatevaccineagainstrotavirusinfectionbasedonrecombinantproteinflicvp6vp8
AT assimbirtsev protectiveactivitystudyofacandidatevaccineagainstrotavirusinfectionbasedonrecombinantproteinflicvp6vp8